

ASX ANNOUNCEMENT

SECTION 249D NOTICE

SYDNEY, Wednesday, 7 October 2020: Cellmid Limited (ASX: CDY) advises that on 2 October 2020 the Company received a defective notice under Section 249D of the *Corporations Act 2001* (Cth) (**Notice**).

The Notice requests the convening of a general meeting of the Company to consider a single resolution seeking the removal of Dr David King as a Director of the Company.

The Company received legal advice that the notice is not valid. Accordingly, at this stage, the Company does not intend to call a general meeting for the removal of the Director noted above.

In any event, Dr King will be standing for re-election at the upcoming Annual General Meeting of the Company, which will precede any general meeting that may be called pursuant to a valid s249D notice.

Further details of any general meeting (if required) will be circulated to shareholders in due course.

Approved for release by the Board of Directors of Cellmid.

End

Contact:

Maria Halasz, CEO

T +612 9221 6830

 @mariahalasz

Cellmid Limited (ASX: CDY)

Cellmid is an Australian life sciences company with a consumer health business and biotech assets in development. Advangen Limited is Cellmid's wholly owned subsidiary engaged in the development and sale of first in class, best in class, clinically validated anti-aging products for hair, skin and body. For further information, please see www.cellmid.com.au and www.evolisproducts.com.au. Cellmid's wholly owned subsidiary, Lynamid, develops innovative novel therapies and diagnostic tests for age related diseases including inflammatory and autoimmune conditions. Most recently Cellmid secured access to a range of SARS-CoV-2 antibody and nucleotide tests, both point of care and laboratory based, from various suppliers.

Forward looking statements

This announcement may have forward-looking statements that are subject to risks and uncertainties. Such statements involve known and unknown risks that may cause the actual results, performance or achievements of Cellmid to be materially different from the statements in this announcement. Actual results could differ materially depending on factors such as the



availability of resources, regulatory environment, the results of marketing and sales activities and competition.